FDASIA Committee Report

David W. Bates MD, MSc, Chair
Committee Membership

- **David W. Bates, Chair**, Brigham and Women’s Hospital
- **Patricia Brennan**, University of Wisconsin-Madison
- **Geoff Clapp**, Better
- **Todd Cooper**, Breakthrough Solutions Foundry, Inc.
- **Meghan Dierks**, Harvard Medical Faculty, Division of Clinical Informatics
- **Esther Dyson**, EDventure Holdings
- **Richard Eaton**, Medical Imaging & Technology Alliance
- **Anura Fernando**, Underwriters Laboratories
- **Lauren Fifield**, Practice Fusion, Inc.
- **Michael Flis**, Roche Diagnostics
- **Elisabeth George**, Philips Healthcare
- **Julian Goldman**, Massachusetts General Hospital/Partners Healthcare
- **T. Drew Hickerson**, Happtique, Inc.
- **Jeffrey Jacques**, Aetna
- **Keith Larsen**, Intermountain Health
- **Robert Jarrin**, Qualcomm Incorporated
- **Mo Kaushal**, Aberdare Ventures/National Venture Capital Association
- **Mary Anne Leach**, Children’s Hospital Colorado
- **Meg Marshall**, Cerner Corporation
- **Mary Mastenbrook**, Consumer
- **Jackie McCarthy**, CTIA - The Wireless Association
- **Anna McCollister-Slipp**, Galileo Analytics
- **Jonathan Potter**, Application Developers Alliance
- **Jared Quoyeser**, Intel Corporation
- **Martin Sepulveda**, IBM
- **Joseph Smith**, West Health
- **Paul Tang**, Palo Alto Medical Foundation
- **Bradley Thompson**, Epstein Becker Green, P.C
- **Michael Swiernik**, MobileHealthRx, Inc.
- **Jodi Daniel**, ONC
- **Bakul Patel**, FDA
- **Matthew Quinn**, FCC
Subgroups

• Taxonomy Subgroup
  – Patti Brennan, RN, PhD, Co-chair
  – Meghan Dierks, MD, Co-chair

• Risk/Innovation Subgroup
  – Keith Larsen, RPh, Co-chair
  – Paul Tang, MD, MS, Co-chair

• Regulation Subgroup
  – Julian Goldman, MD, Co-chair
  – Brad Thompson, JD, MBA, Co-chair
Charge

The Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012 calls for the HHS Secretary to “post a report—within 18 months (or by January 2014)—that contains a proposed strategy and recommendations on a risk-based regulatory framework pertaining to health IT, including mobile applications, that promotes innovation, protects patient safety, and avoids regulatory duplication”.

FDASIA Committee did not have to develop the framework itself—that will be done by FDA, ONC, and FCC—but has been asked to make recommendations which will guide the development of the framework.
Committee Process

• 3 months deliberation
• 1 in-person meeting
• 3 sub-groups
• Dozens of conference calls both in subgroups and larger group, and substantial processing through on-line approaches
• Considered much of the prior work done in this area including IOM committee recommendations
• Substantial input from all three involved agencies
• Public commentary on FDASIA process
Public Comment Summary

Background
• The FDA, ONC and FCC requested public comment on the development of a risk-based regulatory framework and strategy for health information technology through a notice published in the Federal Register on May 30, 2013 (78 FR 32390).
• Comments received by June 30, 2013, were forwarded to the FDASIA workgroup for consideration.

FDASIA Workgroup Review and Consideration
• The workgroup reviewed 14 timely received submissions.
• These submissions and included comments were discussed at the July 26, 2013 meeting.

Consideration of Additional Public Comment
• Consistent with FACA guidelines and at the close of each FDASIA workgroup and sub-workgroup meeting, members solicited and considered any public comments that could inform their recommendations.
Backdrop

– Literature suggests that HIT clearly appears to improve safety overall
  • Many studies which strongly support the benefits\textsuperscript{1,2}
  • However, literature also provides multiple anecdotes that health IT creates new safety risks
– Magnitude of harm and impact of health IT on patient safety is uncertain:
  • Heterogeneous nature of health IT
  • Diverse clinical environments, workflow
  • Limited evidence in the literature
– FDA has authority to regulate HIT but has not done so except in limited ways—authority limited to HIT that meets the definition of a “medical device”

\textsuperscript{1} Bates and Gawande, NEJM 2003
\textsuperscript{2} Health IT and Patient Safety: Building Safer Systems for Better Care
Examples of Problems Associated with HIT

• Mortality rate increased from 2.8% to 6.3% (OR=3.3) in children transferred in for special care after introduction of a commercial CPOE application ¹

• “Flight simulator” of CPOE across 63 hospital EHRs detected only 53% of medication orders which would have been fatal ²

• Clear problem of providers writing electronic orders on the wrong patient because they don’t realize what record they are in ³

• A sensor attached to an asthma rescue inhaler records the location where the rescue medication is used but not the time. When the information is uploaded to a computer the time of the upload, not the time of the medication use, is recorded.

• When even serious safety-related issues with software occur, no central place to report them to, and they do not generally get aggregated at a national level ⁴

¹ Han, Pediatrics 2005
² Metzger, Health Affairs 2010
³ Adelman et al, JAMIA 2013
⁴ Institute of Medicine, Health IT and Patient Safety: Building Safer Systems for Better Care, 2011
Example of Adverse Effect of Regulation

In closed loop systems, one application may drive another process, for example oxygen monitoring might tell an intravenous device to stop delivering narcotics if hypoxemia is detected.

• Reference: Standard ASTM F2761-09, Annex B example B2.1
• References a death related to this intravenous narcotic use case, and a potentially safer system as described above that could be enabled by integrating sensors (e.g. pulse oximetry, respiratory CO2 monitoring) and infusion technology with decision support to close the loop. The limitations of the current state and potential safety benefits of the proposed state are represented in animations at this site: http://www.mdppn.org/MD_PnP_Program___Clinical_S.html
Patient-Controlled Analgesia (PCA)

- Patients can call nurse to request more analgesia, but, when overmedicated, are unable to call for help
- Comprehensive monitoring is not typically used due to high false/nuisance alarm rate (from pulse oximeters, capnographs, etc.)

How can we improve safety of PCA systems?

- Solutions: Required are smarter alarms that combine signals from patient monitors and clinical information system, connected via HIT infrastructure to:
  - Suppress false alarms
  - Detect respiratory depression early, and
  - Real-time decision support that communicates with pump to stop medication infusion prior to injury
- Solution barriers: Lack of regulatory clarity about interoperability, CDS, smart alarm implementation, and concerns about responsibility, liability and adverse event reporting in a multi-vendor (“heterogeneous”) medical device-HIT system
Taxonomy: Assigns HIT to One of Two Categories:
“Subject to risk-based regulatory framework” or
“Not subject to risk-based regulatory framework”

• Guiding principles:
  – All entities addressed by the risk based regulatory framework can be described by a set of defining characteristics
  – Framework must be sufficiently robust to be able to meet future undefined needs
  – Avoid creating an inclusive inventory for determining what is regulated
  – A decision tree approach that emphasizes functionality as a primary scoping criterion
  – Functionality will help distinguish between two similar innovations, one requiring risk-based regulation and one not.
Defining Characteristics of What Should be Included as HIT/ “Eight Key Dimension of HIT”

1. Intended use
2. Conditions of use
3. User type
4. Developer/ ‘Manufacturer’ type
5. Distribution model
6. Phase of the product lifecycle
7. Product categories
8. Other

*More specifics regarding what group believed should be included as HIT are provided in additional slides
HIT as Described Only by Characteristic 7 and Possible Determination

**Possibly subject to Risk based Regulatory Framework**

- EHRs (installed, SaaS)
- Hospital information systems-of-systems
- Decision support algorithms
- Visualization tools for anatomic, tissue images, medical imaging and waveforms
- Health information exchange software
- Electronic/robotic patient care assistants
- Templating software tools for digital image surgical planning

**Likely not subject to the Risk-based Regulatory Framework**

- Claims processing software
- Health benefit eligibility software
- Practice management / Scheduling / Inventory management software
- General purpose communication applications (e.g., email, paging) used by health professionals
- Software using historical claims data to predict future utilization/cost of care
- Cost effectiveness analytic software
- Electronic guideline distribution
- Disease registries
Is use intended to inform or change decision making about:
- initiating
- discontinuing
- modifying
- avoiding
  care interventions or personal health management?

**YES**

In-scope for consideration for risk-based regulation

**NO**

Out-of-scope … defer to existing regulatory framework
Risk Framework

The patient-risk framework enumerates various important factors influencing the risk of software systems and devices. It does not weight or “calculate” any specific risk score for a given product. Rather, it serves as a framework to assess the factors to consider when evaluating the potential risk of patient harm arising out of the use of the system. While the matrix characterizes the relative risk (i.e. “lower risk”, “higher risk”) of certain conditions of each risk factor, these serve as directional guidance only. Exceptions for each relative risk condition exist.

Basic definitions
• Harm – physical [or mental] injury or both to the health of people*
• Hazard – potential source of harm *
• Risk – combination of the probability of occurrence of harm and the severity of that harm *
• Hazardous situation – circumstance in which people, property, or the environment are exposed to one or more hazards*
• Transparency – clear declaration of purpose, intended users, sources of data, sources of content knowledge, application logic applied to data, commercial sponsors of content knowledge
* International Electrotechnical Commission, modified
<table>
<thead>
<tr>
<th>Item</th>
<th>Lower risk</th>
<th>Medium Risk</th>
<th>Higher Risk/More Attention</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Purpose of software product</strong></td>
<td>Information-only; purpose is transparent and clear</td>
<td>Makes recommendations to user</td>
<td>Automated decision making (e.g., intelligent IV pump, AED)</td>
</tr>
<tr>
<td><strong>Intended user(s)</strong></td>
<td>Targeted user(s) are knowledgeable and can safely use product</td>
<td>Makes recommendations to knowledgeable user</td>
<td>Provides diagnosis or treatment advice directly to knowledgeable user</td>
</tr>
<tr>
<td><strong>Severity of injury</strong></td>
<td>Very low probability of harm</td>
<td>Potential for non-life threatening adverse event</td>
<td>Life-threatening potential</td>
</tr>
<tr>
<td><strong>Likelihood of hazardous situation arising</strong></td>
<td>Rare (&lt;1 per 10,000 patient-years)</td>
<td>Unpredictable, but hazardous situation arises &gt; 1:10K pt-yrs and &lt; once a year</td>
<td>Common (arises once per -year)</td>
</tr>
<tr>
<td><strong>Transparency of software operations, data and included content providers</strong></td>
<td>Software output is easy to understand and its “calculation” (data and algorithm) transparent</td>
<td>Software operates transparently and output is understandable by software expert</td>
<td>“Black box”</td>
</tr>
<tr>
<td><strong>Ability to mitigate harmful conditions</strong></td>
<td>Human intermediary knowledgeable and empowered to intervene to prevent harm</td>
<td>Human intermediary may be (but not routinely) involved</td>
<td>Closed loop (no human intervention)</td>
</tr>
<tr>
<td><strong>Complexity of software and its maintenance</strong></td>
<td>Application of mature, widely adopted technologies with information output that is easy to understand by the user</td>
<td>Medium complexity. Testing procedures exist that reliably assess patient-safety risk profile of product.</td>
<td>Complexity of data collection and “transformation” involved in producing output is significant. Difficult to test reliably for all safety risks</td>
</tr>
<tr>
<td><strong>Complexity of implementation and upgrades</strong></td>
<td>The “build” and configuration of the software is straight-forward and does not materially affect the integrity of the output. Safety upgrades can be accomplished easily.</td>
<td>The “build” and configuration of the software is moderately complex, but “guard rails” significantly limit types of changes that might induce life-threatening risk.</td>
<td>The “build” and configuration of the software is complex and can introduce substantial changes that can induce serious risk. Limited or no “guard rails.”</td>
</tr>
<tr>
<td><strong>Complexity of training and use</strong></td>
<td>The software system output is clear and easy to interpret. Minimal training needed.</td>
<td>Moderate complexity. Less than 2 hr of training required.</td>
<td>The complexity of the user interface and density of data presented can cause important errors or oversights that can lead to serious risk. Formal training necessary.</td>
</tr>
<tr>
<td><strong>Use as part of more comprehensive software/hardware system</strong></td>
<td>Used as a standalone product, or output is unambiguously used as part of larger integrated system. Certified to specific hardware. Redundancy reduces single points of failure</td>
<td>Software interacts with 1-3 other systems with mature, well described interfaces</td>
<td>Almost always used as part of a larger software system AND output is subject to interpretation or can be configured in multiple ways whose mis-interpretation may induce harm. [e.g., DDI thresholds].</td>
</tr>
<tr>
<td><strong>Network connectivity, standards, security</strong></td>
<td>Wired and wireless licensed spectrum</td>
<td>Wireless spectrum that is licensed by rule with interference protection and low risk of harmful interference</td>
<td>Wireless unlicensed spectrum, which has no protection from harmful interference</td>
</tr>
</tbody>
</table>

**FDASIA: Framework for Risk and Innovation DIMENSIONS of ASSESSING RISK of PATIENT HARM (v2.4)**
**DISCUSSION USE CASE: mHealth Nutrition app using DRAFT v2.4 Patient-Safety Risk Framework**

<table>
<thead>
<tr>
<th>Item</th>
<th>Lower risk</th>
<th>Medium Risk</th>
<th>Higher Risk / More Attention</th>
</tr>
</thead>
<tbody>
<tr>
<td>Purpose of software product</td>
<td>Information-only; purpose is transparent and clear</td>
<td>Makes recommendations to user</td>
<td>Automated decision making (e.g., intelligent IV pump, AED)</td>
</tr>
<tr>
<td>Intended user(s)</td>
<td>Targeted user(s) are knowledgeable and can safely use product</td>
<td>Makes recommendations to knowledgeable user</td>
<td>Provides diagnosis or treatment advice directly to knowledgeable user</td>
</tr>
<tr>
<td>Severity of injury</td>
<td>Very low probability of harm</td>
<td>Potential for non-life threatening adverse event</td>
<td>Life-threatening potential</td>
</tr>
<tr>
<td>Likelihood of hazardous situation arising</td>
<td>Rare (&lt;1 per 10,000 patient-years)</td>
<td>Unpredictable, but hazardous situation arises &gt; 1:10K pt-yrs and &lt; once a year</td>
<td>Common (arises once per year)</td>
</tr>
<tr>
<td>Transparency of software operations and data</td>
<td>Software output is easy to understand and its “calculation” (data and algorithm) transparent</td>
<td>Software operates transparently and output is understandable by software expert</td>
<td>“Black box”</td>
</tr>
<tr>
<td>Ability to mitigate harmful conditions</td>
<td>Human intermediary knowledgeable and empowered to intervene to prevent harm</td>
<td>Human intermediary may be (but not routinely) involved</td>
<td>Closed loop (no human intervention)</td>
</tr>
<tr>
<td>Complexity of software and its maintenance</td>
<td>Application of mature, widely adopted technologies with information output that is easy to understand by the user</td>
<td>Medium complexity. Testing procedures exist that reliably assess patient-safety risk profile of product.</td>
<td>Complexity of data collection and “transformation” involved in producing output is significant. Difficult to test reliably for all safety risks</td>
</tr>
<tr>
<td>Complexity of implementation and upgrades</td>
<td>The “build” and configuration of the software is straight-forward and does not materially affect the integrity of the output. Safety upgrades can be accomplished easily.</td>
<td>The “build” and configuration of the software is moderately complex, but “guard rails” significantly limit types of changes that might induce life-threatening risk.</td>
<td>The “build” and configuration of the software is complex and can introduce substantial changes that can induce serious risk. Limited or no “guard rails.”</td>
</tr>
<tr>
<td>Complexity of training and use</td>
<td>The software system output is clear and easy to interpret. Minimal training needed.</td>
<td>Moderate complexity. Less than 2 hr of training required.</td>
<td>The complexity of the user interface and density of data presented can cause important errors or oversights that can lead to serious risk. Formal training necessary.</td>
</tr>
<tr>
<td>Use as part of more comprehensive software/hardware system</td>
<td>Used as a standalone product, or output is unambiguously used as part of larger integrated system. Certified to specific hardware. Redundancy reduces single points of failure</td>
<td>Software interacts with 1-3 other systems with mature, well described interfaces</td>
<td>Almost always used as part of a larger software system AND output is subject to interpretation or can be configured in multiple ways whose mis-interpretation may induce harm. [e.g., DDI thresholds].</td>
</tr>
<tr>
<td>Network connectivity, standards, security</td>
<td>Wired and wireless licensed spectrum</td>
<td>Wireless spectrum that is licensed by rule with interference protection and low risk of harmful interference</td>
<td>Wireless unlicensed spectrum, which has no protection from harmful interference</td>
</tr>
</tbody>
</table>
## DISCUSSION USE CASE: Closed-Loop Insulin Pump with Implanted Continuous Glucose Monitor using DRAFT v2.4

### Patient-Safety Risk Framework

<table>
<thead>
<tr>
<th>Item</th>
<th>Lower risk</th>
<th>Medium Risk</th>
<th>Higher Risk / More Attention</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Purpose of software product</strong></td>
<td>Information-only; purpose is transparent and clear</td>
<td>Makes recommendations to user</td>
<td><strong>Automated decision making (e.g., intelligent IV pump, AED)</strong></td>
</tr>
<tr>
<td><strong>Intended user(s)</strong></td>
<td>Targeted user(s) are knowledgeable and can safely use product</td>
<td>Makes recommendations to knowledgeable user</td>
<td><strong>Provides diagnosis or treatment advice directly to knowledgeable user</strong></td>
</tr>
<tr>
<td><strong>Severity of injury</strong></td>
<td>Very low probability of harm</td>
<td>Potential for non-life threatening adverse event</td>
<td>Life-threatening potential</td>
</tr>
<tr>
<td><strong>Likelihood of hazardous situation arising</strong></td>
<td>Rare (&lt;1 per 10,000 patient-years)</td>
<td><strong>Unpredictable, but hazardous situation arises &gt; 1:10K pt-yrs and &lt; once a year</strong></td>
<td>Common (arises once per year)</td>
</tr>
<tr>
<td><strong>Transparency of software operations and data and included content providers</strong></td>
<td>Software output is easy to understand and its “calculation” (data and algorithm) transparent</td>
<td>Software operates transparently and output is understandable by software expert</td>
<td>“Black box”</td>
</tr>
<tr>
<td><strong>Ability to mitigate harmful conditions</strong></td>
<td>Human intermediary knowledgeable and empowered to intervene to prevent harm</td>
<td><strong>Human intermediary may be (but not routinely) involved</strong></td>
<td>Closed loop (no human intervention)</td>
</tr>
<tr>
<td><strong>Complexity of software and its maintenance</strong></td>
<td>Application of mature, widely adopted technologies with information output that is easy to understand by the user</td>
<td><strong>Medium complexity. Testing procedures exist that reliably assess patient-safety risk profile of product.</strong></td>
<td>Complexity of data collection and “transformation” involved in producing output is significant. Difficult to test reliably for all safety risks</td>
</tr>
<tr>
<td><strong>Complexity of implementation and upgrades</strong></td>
<td>The “build” and configuration of the software is straight-forward and does not materially affect the integrity of the output. Safety upgrades can be accomplished easily.</td>
<td><strong>The “build” and configuration of the software is moderately complex, but “guard rails” significantly limit types of changes that might induce life-threatening risk.</strong></td>
<td>The “build” and configuration of the software is complex and can introduce substantial changes that can induce serious risk. Limited or no “guard rails.”</td>
</tr>
<tr>
<td><strong>Complexity of training and use</strong></td>
<td>The software system output is clear and easy to interpret. Minimal training needed.</td>
<td><strong>Moderate complexity. Less than 2 hr of training required.</strong></td>
<td>The complexity of the user interface and density of data presented can cause important errors or oversights that can lead to serious risk. Formal training necessary.</td>
</tr>
<tr>
<td><strong>Use as part of more comprehensive software/hardware system</strong></td>
<td>Used as a standalone product, or output is unambiguously used as part of larger integrated system. Certified to specific hardware. Redundancy reduces single points of failure</td>
<td><strong>Software interacts with 1-3 other systems with mature, well described interfaces</strong></td>
<td>Almost always used as part of a larger software system AND output is subject to interpretation or can be configured in multiple ways whose mis-interpretation may induce harm. [e.g., DDI thresholds].</td>
</tr>
<tr>
<td><strong>Network connectivity, standards, security</strong></td>
<td>Wired and wireless licensed spectrum</td>
<td><strong>Wireless spectrum that is licensed by rule with interference protection and low risk of harmful interference</strong></td>
<td>Wireless unlicensed spectrum, which has no protection from harmful interference</td>
</tr>
<tr>
<td>Item</td>
<td>Lower risk</td>
<td>Medium Risk</td>
<td>Higher Risk / More Attention</td>
</tr>
<tr>
<td>----------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Purpose of software product</td>
<td>Information-only; purpose is transparent and clear</td>
<td><strong>Makes recommendations to user</strong></td>
<td>Automated decision making (e.g., intelligent IV pump, AED)</td>
</tr>
<tr>
<td>Intended user(s)</td>
<td>Targeted user(s) are knowledgeable and can safely use product</td>
<td><strong>Makes recommendations to knowledgeable user</strong></td>
<td><strong>Provides diagnosis or treatment advice directly to knowledgeable user</strong></td>
</tr>
<tr>
<td>Severity of injury</td>
<td>Very low probability of harm</td>
<td>Potential for non-life threatening adverse event</td>
<td><strong>Life-threatening potential</strong></td>
</tr>
<tr>
<td>Likelihood of hazardous situation arising</td>
<td>Rare (&lt;1 per 10,000 patient-years)</td>
<td>Unpredictable, but hazardous situation arises &gt; 1:10K pt-yrs and &lt; once a year</td>
<td><strong>Common</strong> (arises once per year)</td>
</tr>
<tr>
<td>Transparency of software operations and data and included content providers</td>
<td>Software output is easy to understand and its &quot;calculation&quot; (data and algorithm) transparent</td>
<td><strong>Software operates transparently and output is understandable by software expert</strong></td>
<td>&quot;Black box&quot;</td>
</tr>
<tr>
<td>Ability to mitigate harmful conditions</td>
<td><strong>Human intermediary knowledgeable and empowered to intervene to prevent harm</strong></td>
<td>Human intermediary may be (but not routinely) involved</td>
<td><strong>Closed loop (no human intervention)</strong></td>
</tr>
<tr>
<td>Complexity of software and its maintenance</td>
<td>Application of mature, widely adopted technologies with information output that is easy to understand by the user</td>
<td>Medium complexity. Testing procedures exist that reliably assess patient-safety risk profile of product.</td>
<td><strong>Complexity of data collection and “transformation” involved in producing output is significant. Difficult to test reliably for all safety risks</strong></td>
</tr>
<tr>
<td>Complexity of implementation and upgrades</td>
<td>The “build” and configuration of the software is straight-forward and does not materially affect the integrity of the output. Safety upgrades can be accomplished easily.</td>
<td>The “build” and configuration of the software is moderately complex, but “guard rails” significantly limit types of changes that might induce life-threatening risk.</td>
<td>The “build” and configuration of the software is complex and can introduce substantial changes that can induce serious harm. Limited or no “guard rails.”</td>
</tr>
<tr>
<td>Complexity of training and use</td>
<td>The software system output is clear and easy to interpret. Minimal training needed.</td>
<td>Moderate complexity. Less than 2 hr of training required.</td>
<td>The complexity of the user interface and density of data presented can cause important errors or oversights that can lead to serious risk. Formal training necessary.</td>
</tr>
<tr>
<td>Use as part of more comprehensive software/hardware system</td>
<td>Used as a standalone product, or output is unambiguously used as part of larger integrated system. Certified to specific hardware. Redundancy reduces single points of failure</td>
<td>Software interacts with 1-3 other systems with mature, well described interfaces</td>
<td><strong>Almost always used as part of a larger software system AND output is subject to interpretation or can be configured in multiple ways whose mis-interpretation may induce harm. [e.g., DDI thresholds].</strong></td>
</tr>
<tr>
<td>Network connectivity, standards, security</td>
<td><strong>Wired and wireless licensed spectrum</strong></td>
<td>Wireless spectrum that is licensed by rule with interference protection and low risk of harmful interference</td>
<td>Wireless unlicensed spectrum, which has no protection from harmful interference</td>
</tr>
</tbody>
</table>

**DISCUSSION USE CASE: EHR using DRAFT v2.4 Patient-Safety Risk Framework**
Observations

Application of Use Cases to Risk Framework

• Easier to classify lower risk applications (attributes)
  – Standalone
  – Narrowly defined functions
  – Less variability in context of use

• Harder to classify more complex software precisely ("it depends")
  – More dependent on context of use
  – More complex software to develop and QA
  – Greater effort and expertise required to implement
  – More interfaces to other systems
  – Greater reliance on QMS process and risk controls for known failure rates
Policy Implications

• Define clearer criteria for software functions that are not regulated, but might have labeling requirements to promote transparency

• Define clearer criteria for software functions that warrant regulation, or at least greater attention

• Create a robust surveillance mechanism to track adverse events and near misses for the majority of software functions that lie in between
# Current FDA Medical Device Regulation

<table>
<thead>
<tr>
<th>Class</th>
<th>Risk</th>
<th>FDA Requirements</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enforcement Discretion</td>
<td>Variable</td>
<td>Requirements are scalable and some times none -- based on FDA authority to focus regulatory requirements outside of traditional classification categories</td>
</tr>
<tr>
<td>Class I</td>
<td>Lower</td>
<td>• Other process requirements -- aka general controls (e.g. adverse event reporting, facility registration and listing)</td>
</tr>
</tbody>
</table>
|                     | Low           | Same as Lower risk, but additional process requirements  
|                     |               | • Quality system requirements** for product development and maintenance that go beyond normal ISO quality standards                               |
| Class II            | Medium – Low  | Same as class I low risk, but NO premarket clearance requirement  
|                     |               | • Technology/device specific expectations are set through special controls guidance.                                                        |
|                     | Medium        | Same as class I low risk, but also premarket clearance requirement  
|                     |               | • manufacturer proves to FDA that device is “substantially equivalent” to another device already on the market. FDA to make a determination (510(k) clearance) within 90 days. |
| Class III           | Higher        | Same as class I, but also premarket approval requirement  
|                     |               | • More detailed approval requirements (including clinical evidence, product development methods, etc). FDA to make a determination (approval or denial) within 180 days of application. |

**Quality Systems Manual --  
# Medical Device Regulation

## Innovation Impact Review

<table>
<thead>
<tr>
<th>Pros</th>
<th>Cons</th>
</tr>
</thead>
</table>
| • Process control, not product definition:  
  – Consistent manufacturing process that can be applied to software  
  – Supports innovation in new products  
| • Clarity  
  – Who is subject to regulation?  
  – Implementation barriers – knowledge & overly prescriptive |
| • Good manufacturing Process has increased the confidence in resulting products  
| • Geared especially but not exclusively to physical devices  
  – Turnaround time  
  – Configuration and extension  
  – “Class Up” effect on software working with device  
  – But, can be applied to software with some modifications recognizing differences between physical devices and software |
| • Contains a post-marketing surveillance program  
| • Blood Bank use case  
  – Commonly presented as a negative use case  
  – Requires more in-depth review for lessons learned |
| • Entry impedance:  
  – Need way lower burden of applying these regulations to new development and to products that started small without regulation, but then have regulation applied after the development and initial use |
Current ONC Certification Regulation of EHRs
Innovation Impact Review

• Motivation: defined product
  – Government is funding a capital improvement to healthcare practice (link to Meaningful Use)
  – Therefore, obligation to promote good products
  – Therefore, certification of the products

• Effect on innovation:
  – Specification of specific software behaviors and certifying specific test behaviors limits innovation
  – Narrows solutions to problems to a prescribed solution
  – Working to the test – “Compliance Innovation”
  – Justified only when there is an overriding societal benefit (e.g., interoperability, specific patient safety concerns)
Current ONC Certification Regulation

Specific Recommendations to Promote Innovation

• Judicious use of specific functional requirements.
  – Limit specific functional requirements unless there is a specific public health or patient safety issue
  – Regulatory description of other features should be in higher level descriptive, not functional design, terms.

• Flexible compliance measures.
  – Show flexibility in the certifying session to allow for multiple approaches to the desired feature.
  – Example: certification standards for user centered design leave open the specific implementation.

• Avoid requirements that empower a single, external certification body.

• Increase predictability
  – Staging the definition of the requirements versus having a defined roadmap of features
  – Re-certification criteria
Comparison of Approaches
Innovation Impact Review

Medical Device Regulation

- Process control – e.g., current good manufacturing process
- Pre-marketing approval – in some cases
- Impact
  - Can be positive when combining software from different sources – increased trust
  - Lack of clarity (flipside of regulatory discretion) yields policy uncertainty
  - Entry impedance
    - Clarity on requirements & process – purpose of AAMI report
    - Late entry into process with existing product
  - Continued overhead: heavy process versus Agile development – need for scaling of process
  - If fully applied to HIT and local implementation, devastating to market – Blood Bank example

Certification Regulation

- Product definition
- “Best Practice” feature definitions
- Pre-use approval
- Impact
  - Reduced flexibility (specific detailed requirements), reduced innovation
  - Empowered added private regulation
  - Non-productive work to test – “Compliance Innovation”
  - Less market neutral – favors existing software with defined features
Regulations—Questions Addressed

1. Are the three regulatory systems – ONC, FCC and FDA – deficient in any way with regard to how HIT is regulated?

2. Are there ambiguities in the three regulatory systems that need to be clarified so that HIT vendors and others can proceed more easily to innovate?

3. Do any of the three regulatory systems duplicate one another, or any other legal, regulatory or industry requirement?

4. Setting aside existing approaches, is there a better way to assure that innovation is permitted to bloom, while safety is assured?
# FDA Issues

A = Ambiguous, B = Broken at the written law level, C = Existing mechanism for immediate relief

<table>
<thead>
<tr>
<th>Item</th>
<th>Issue: A, B or C</th>
<th>Description of challenge</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wellness/disease</td>
<td>A, B, C</td>
<td>FDA needs to explain how to discern disease related claims from wellness, and needs to deregulate low risk disease related claims</td>
</tr>
<tr>
<td>borderline</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accessory issues</td>
<td>A, B, C</td>
<td>FDA needs to explain its position on which basic IT elements are regulated when connected to a medical device, and deregulate or down-regulate those that are low risk</td>
</tr>
<tr>
<td>CDS software</td>
<td>A, C</td>
<td>FDA needs to explain which forms of clinical decision support software it regulates</td>
</tr>
<tr>
<td>Software modularization</td>
<td>A, C</td>
<td>FDA needs to specify its rules for deciding the regulatory status of software modules either incorporated into a medical device, or accessed by a medical device</td>
</tr>
</tbody>
</table>
## FDA Issues

A = Ambiguous, B = Broken at the written law level, C = Existing mechanism for immediate relief

<table>
<thead>
<tr>
<th>Item</th>
<th>Issue: A, B or C</th>
<th>Description of challenge</th>
</tr>
</thead>
<tbody>
<tr>
<td>QS application to standalone software</td>
<td>A, C</td>
<td>FDA needs to explain how the quality system requirements and facility registration apply to manufacturing of standalone software</td>
</tr>
<tr>
<td>Premarket requirements for interoperable devices</td>
<td>A</td>
<td>FDA needs to adopt a paradigm for reviewing software that is intended to be part of a larger, but unspecified, network. Could build on the efforts of a working group of companies, academics, and hospitals that developed and submitted a pre-IDE regulatory submission to help refine the FDA clearance process.</td>
</tr>
<tr>
<td>Postmarket requirements for networks</td>
<td>A, B</td>
<td>Responsibilities for reporting adverse events and conducting corrective actions can be clarified, but also likely need a new approach that reflects shared responsibility across users, producers, and across regulatory agencies</td>
</tr>
</tbody>
</table>
Current FDA Program Mechanisms that Could Enable Innovation

• FDA should actively establish a policy of “Enforcement Discretion” for lowest-risk HIT, where enforcement of regulations is inappropriate
• FDA should assess exemption from GMP for lower-risk HIT
• FDA should expedite guidance on HIT software, mobile medical apps and related matters
• FDA lacks internal coordination on HIT software, and mobile medical apps policies and regulatory treatment
• FDA should utilize external facing resources to proactively educate the public about how policies and regulation impact HIT and MMA
• There may exist a need for additional funding to appropriately staff and build FDA expertise in HIT and mobile medical apps
## ONC Issues

A = Ambiguous,  B = Broken at the written law level,  C= Capability that is underused

<table>
<thead>
<tr>
<th>Item</th>
<th>Issue: A or B</th>
<th>Description of challenge</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mandatory elements</td>
<td>B</td>
<td>ONC program does not include capability in law enforcement, nor its programs framed with mandates where necessary</td>
</tr>
<tr>
<td>Assurance of Safe</td>
<td>A</td>
<td>Safety depends on appropriate post-installation configuration. No means to educate or require compliance with documented and evolving best practices</td>
</tr>
<tr>
<td>Configuration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Certification program</td>
<td>B</td>
<td>ONC should avoid regulatory rules and certification test cases that endorse a specific solution or implementation to a desired feature.</td>
</tr>
<tr>
<td>Program review</td>
<td>C</td>
<td>ONC does a good job of periodically reviewing its programs and criteria and eliminating those that are no longer necessary. We would like to see them do more of this.</td>
</tr>
</tbody>
</table>
## FCC Issues

A = Ambiguous and B = Broken at the written law level

<table>
<thead>
<tr>
<th>Item</th>
<th>Issue: A or B</th>
<th>Description of challenge</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-Installation</td>
<td>A</td>
<td>Planning for deployment of wireless technologies is difficult in spectrum-crowded, interference-prone environments (i.e. most hospitals). Pre-clinical test and evaluation tools and environments could help manufacturers and healthcare delivery organizations. (FCC “wireless test bed” initiative)</td>
</tr>
<tr>
<td>Assessment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Post-installation</td>
<td>A</td>
<td>Spectrum management and identification, diagnosing, and resolving wireless co-existence/Electromagnetic Compatibility (EMC) problems that affect HIT and medical device performance (in healthcare facilities and mHealth environments)</td>
</tr>
<tr>
<td>Surveillance</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Cross-Agency Issues

<table>
<thead>
<tr>
<th>Item</th>
<th>Description of challenge</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coverage of interoperability issues FDA/ONC</td>
<td>Unclear and incomplete responsibility over ensuring needed interoperability. ONC may regulate HIT/medical device interface and FDA regulates med device/med device interface. But same med device (e.g. infusion pump) could be installed in either configuration. Who is responsible for resolving? More generally, who will require interoperability when products need to be interoperable to be used safely?*</td>
</tr>
<tr>
<td>FCC/FDA review</td>
<td>FCC and FDA do not coordinate their review processes on converged medical devices that are brought independently before both agencies (FCC’s equipment authorization program and FDA’s premarket review). Coordination between agencies should be transparent and help ensure consistency thereby eliminating duplicative, time consuming, and costly hurdles.</td>
</tr>
<tr>
<td>FCC/FDA conformity assessment</td>
<td>Incomplete/missing clinically focused wireless conformity assessment tools that would facilitate safety and co-existence analysis</td>
</tr>
</tbody>
</table>

*See interoperability FDA Pre-IDE regulatory research project: http://www.mdpnp.org/MD_PnP_Program___MDISWG.html
# Issues Error/Adverse Event Reporting

A = Ambiguous and  B = Broken at the written law level

<table>
<thead>
<tr>
<th>Item</th>
<th>Issue: A or B</th>
<th>Description of challenge</th>
</tr>
</thead>
<tbody>
<tr>
<td>Difficult to obtain data for system performance analysis</td>
<td>A</td>
<td>When medical device-HIT “system related” adverse events occur, it is often difficult or impossible to find the root cause of the failure. Data logs may be incomplete, inaccessible, non-existent, not in standardized format.</td>
</tr>
<tr>
<td>Root cause of events may span regulated and non-regulated space</td>
<td>B</td>
<td>What is best model for reporting and analyzing issues with systems of devices/equipment that span (multiple agency) regulated and non-regulated space? Group surveyed existing approaches: NHTSA, CPSC, ASRS, FDA MedSun and ASTERD, NTSB, and PSOs. Further analysis needed. Notion of a new construct - Health IT Safety Administration(^1) (“HITSA”) was discussed. Broad stakeholder involvement emphasized.</td>
</tr>
<tr>
<td>Adverse events should be accessible early and broadly</td>
<td>B</td>
<td>Current reporting pathway often does not facilitate timely resolution. Broader access to safety and performance data to enable timely improvements was emphasized.(^2)</td>
</tr>
</tbody>
</table>

---

Specific Recommendations (I)

- FDA and HIT:
  - HIT should not be subject to FDA premarket requirements, except:
    - Medical device accessories (to be defined clearly by FDA)
    - Certain forms of high risk clinical decision support, such as Computer Aided Diagnostics (to be defined clearly by FDA)
    - Higher risk software use cases per the Risk WG report, including those where the intended use elevates aggregate risk

- Vendors should be required to list products which are considered to represent at least some risk if a non-burdensome approach can be identified to doing so\(^1\)

- To develop better post-market surveillance of HIT, a collaborative process with stakeholder participation is needed:
  - Better post-market surveillance of HIT is needed
    - Should include user self-reporting and reporting from vendors and transparency\(^2\)
    - Also post-implementation testing to ensure key safety-related decision support is in place\(^3\)
  - Approaches are needed to allow aggregation of safety issues at the national level, including federal support
  - Which agency should perform the above will need to be determined but cross-agency collaboration will be essential

- This approach would be provisional, to be re-examined periodically

---

1) Listing could be different depending on the type of software, to minimize burden.
2) With respect to reporting and how it should be structured, we generally endorse the recommendations of the IOM Committee, which suggested that reporting should be voluntary from users, and that vendors should be mandated to forward spontaneous reports that they receive, using an NTSB-like model. This would involve use of common formats, and how to implement this would be something which the tri-agencies would need to work out. We note that Patient Safety Organizations (PSOs) today provide protections to providers, but not to vendors, and that it might be helpful for PSOs to provide some protections to vendors as that could boost reporting for minor infractions.
3) Metzger, Health Affairs 2010
Specific Recommendations (II)

• We recommend the following areas be further developed which may be accomplished through either private and/or public sector efforts:
   Adoption of existing standards and creation and adoption of needed new standards addressing areas such as interoperability
   A public process for customer rating of HIT to enhance transparency¹

¹) Should be facilitated by an independent group using validated measurement results
Measurement of Regulatory Impact on Innovation
General Attributes / Requirements

IOM Report, Appendix D

Stringency  

Innovation

Flexibility

Innovation
– Defined as the number of implementation paths to meet compliance.

Information

Innovation
– Defined as if a regulation promotes more or less complete information in the market.
Lessons Learned

Recommendations for a New Regulatory Framework

• Certification regimens should be used judiciously
  – When specifying specific implementations, they can narrow creativity and innovation to a specific or narrowed list of solutions
    • Some instances where narrowing choice desirable: e.g., interoperability standards
  – Innovation impact
    • Channel energy into working to the test – compliance innovation
    • Channel the discussion to definitional terms rather than meeting the market needs

• Transparency of results to supplement or replace certification
  – Instead of a certification process to differentiate the market, use transparency
  – Transparency in the marketplace is more efficient and richer in content
    • Certification just reveals that the system passed the certification test and all vendors will – at that point, there is no differentiation

• National goals should be encouraged – JCAHO, Meaningful Use
  – They meet the “flexibility” test (Appendix D – IOM Report)
  – Set problem agenda, not product agenda
  – They do change and, if well set, correct the market and create markets
  – Where the market goes, vendors will follow
Innovation Requirements

Sources of Innovation: Full Spectrum of the SocioTechnical System

• Developed software – vendor and local
• Software setup / customization / extensions
  – Integration with medical processes – sociotechnical system
• Combining technologies
  – Communication devices
  – Predictable combinations (e.g., HL7 interfaces)
  – Non-predictable combinations (e.g., end user combination of available technologies – software and hardware)
Summary of Recommendations for a New Framework (I)

• National accountability
  – Outcomes assessment rather than product definitions
  – International/national standards for quality process – measureable and transparent
  – International/national interoperability standards to lower the entry cost
  – Encourage configuration and extension to support process and solve problems
  – Transparency of product and results
  – Support ability to experiment or iteratively develop
  – Aggregation of safety issues at a national level
Summary of Recommendations for a New Framework (II)

• Local control, local accountability
  – Design, document, and prove a local control system
    • Could be co-owned with vendor
  – Accreditation of the software implementation process – e.g., through an entity such as JCAHO
  – Scope
    • Local configuration of software
    • Local extensions of software
    • Ability to iteratively develop, implement, and measure changes
    • Integration with medical processes
    • Training of end users
    • Sharing of lessons learned
    • Surveillance by the organization
    • Post-implementation testing
To encourage innovation and shared learning environments, the committee adopted the following general principles for government oversight:

- Focus on shared learning,
- Maximize transparency,
- Be non-punitive,
- Identify appropriate levels of accountability, and
- Minimize burden
# Comparison Between Current Approach and a New Framework

<table>
<thead>
<tr>
<th>Current Regulation</th>
<th>Learning Environment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Defined solution</td>
<td>Multiple solutions</td>
</tr>
<tr>
<td>Slow response to innovation and problems</td>
<td>Continuous innovation</td>
</tr>
<tr>
<td>Opaque results</td>
<td>Continuous measurement of results</td>
</tr>
<tr>
<td>Discourages participation</td>
<td>Encourages participation</td>
</tr>
</tbody>
</table>
Overall Summary

• Have described a taxonomy for considering what the bounds are for what is HIT and might be considered for regulation
• Have proposed recommendations around development of a risk framework which may be useful in stratifying HIT by risk and assessing what if any regulation is needed
• Have described current regulatory frameworks, potential new approaches, and deficiencies, ambiguities and duplication in current frameworks
• Have described what we believe will be helpful to promote innovation in both the short and long term and maintain patient safety
• Have tried to illustrate with use cases all the above
Overall Recommendations (I)

- Definition of what is included in HIT should be broad but have also described exclusions
- Patient-safety risk framework and examples should be used as building blocks to develop a more robust and transparent framework which would allow application of oversight by level of risk
- The agencies should address the deficiencies, ambiguities and duplication the FDASIA group has identified
- New framework(s) with some of the characteristics aimed at stimulating innovation may be helpful
Overall Recommendations (II)

• Substantial additional regulation of HIT beyond what is currently in place is not needed and would not be helpful (should be Class 0), except for:
  ✓ Medical device data systems (MDDS)
  ✓ Medical device accessories
  ✓ Certain forms of high risk clinical decision support
  ✓ Higher risk software use cases

  • For the regulated software, it will be important for the FDA to improve the regulatory system to accommodate the characteristics that make software development, distribution and use different from physical devices

• New risk framework(s) should support reevaluation of what is currently regulated as well as new HIT
Overall Recommendations (III)

• In addition, we believe that as recommended by the IOM Committee:
  – Vendors should be required to list products which are considered to represent at least some risk and a non-burdensome approach should be developed for this
  – Better post-market surveillance of HIT is needed
    • Should include standard formatting of involved reports
    • Transparency of results
    • Also post-implementation testing
  – Approaches needed to allow aggregation of safety issues at the national level, including federal support to enable this
  – FDA and other agencies need to take steps to strongly discourage vendors from engaging in practices that discourage or limit the free flow of safety-related information\(^1\)
  – How to organize the governance of this should be addressed by a cross-agency group, which should include key stakeholders

1) Health IT and Patient Safety: Building Safer Systems for Better Care